De Novo Malignancy in Transplant Recipients

De novo malignancy refers to cancers that arise after transplantation in a recipient, as opposed to cancer transmitted with the donor organ or recurrence of a pre-existing tumour. Such cancers occur at substantially higher rates than in the general population and are a major long-term cause of death with a functioning graft, reflecting the loss of immune surveillance under chronic immunosuppression.

Definition

A de novo malignancy in a transplant recipient is a new primary cancer that develops after transplantation, distinct from donor-transmitted cancer or recurrence of a malignancy the recipient had before transplant; collectively these cancers occur with increased frequency that is attributed to immunosuppression-related loss of immune control.

Scope

This topic covers the overall and site-specific excess cancer risk after solid-organ transplantation, the central role of impaired immune surveillance and oncogenic viruses, and the distinctive pattern in which virus-related and immune-related cancers are most elevated. It is reference-educational and does not provide screening schedules or treatment guidance.

Core questions

• How much higher is cancer incidence after transplantation, and which cancers are most increased?
• Why do virus-associated and immune-related cancers dominate the excess risk?
• How does immunosuppression contribute to carcinogenesis beyond simple immune suppression?
• How does the post-transplant cancer pattern compare with that seen in other immunodeficiency states?

Key concepts

• De novo versus donor-transmitted versus recurrent cancer
• Loss of immune surveillance
• Oncogenic viruses (EBV, HHV-8, HPV, others)
• Standardized incidence ratio (SIR)
• Virus-related and immune-related cancer excess
• Skin cancers and post-transplant lymphoproliferative disorder as leading entities

Mechanisms

Chronic immunosuppression diminishes the immune system's ability to recognize and eliminate transformed cells and to control oncogenic viruses, so cancers driven by viral infection are disproportionately increased; Epstein-Barr virus underlies much lymphoproliferative disease, human herpesvirus 8 is linked to Kaposi sarcoma, and human papillomavirus contributes to anogenital and some other cancers. Population studies confirm that the excess risk is broad but skewed toward these infection- and immune-related cancers rather than uniformly across all tumour types. Some immunosuppressive agents may also have direct pro-oncogenic or, conversely, antiproliferative properties, so the net effect reflects both the degree of immunosuppression and the specific drugs used, as discussed in the immunosuppression literature.

Clinical relevance

Because cancer is a leading cause of late mortality after transplantation, cancer surveillance is part of long-term recipient care, and understanding which cancers are most elevated informs how that surveillance is conceived. This entry summarizes the epidemiology and mechanisms of post-transplant cancer for orientation only; it does not provide screening intervals, risk-reduction regimens, or treatment recommendations.

Epidemiology

In a large US registry linkage, Engels and colleagues found that solid-organ transplant recipients had roughly twice the overall cancer incidence of the general population, with markedly elevated risks for cancers such as non-Hodgkin lymphoma, lung, liver, and kidney cancers and for several virus-associated tumours. Grulich and colleagues' meta-analysis showed that the pattern of elevated cancers in transplant recipients closely parallels that in people with HIV/AIDS, supporting immune deficiency and oncogenic viruses as shared drivers. Skin cancers and post-transplant lymphoproliferative disorder are among the most characteristic entities.

History

As graft and patient survival improved, the long-term oncologic cost of immunosuppression became increasingly apparent. The convergence in the 2000s of large transplant registries with cancer registries enabled population-scale estimates of site-specific risk, and comparative analyses with HIV/AIDS cohorts reinforced the central role of immune deficiency and oncogenic infection, establishing de novo malignancy as a defining long-term concern in transplantation.

Key figures

• Eric A. Engels
• Andrew E. Grulich
• Philip F. Halloran

Seminal works

• engels-2011
• grulich-2007

Frequently asked questions

Why do transplant recipients get more cancer than the general population?

Long-term immunosuppression weakens the immune surveillance that normally detects and removes abnormal cells and controls cancer-causing viruses, so virus-related and immune-related cancers in particular occur more often.

What does 'de novo' malignancy mean in transplantation?

It refers to a brand-new cancer that develops in the recipient after the transplant, as distinct from a cancer transmitted within the donor organ or a recurrence of a cancer the recipient already had.